Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T15:01:31.846Z.
Consensus retrieved: 2026-10-06T09:10:31.735Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T15:01:31.846Z.
Quote observation: 2026-10-06T15:00:38.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 533c4696450707580a389d0c8167e09da333cd728c1767827588ef029f48caf5
Forward PE Ratio (N/A) = Dated Quote Price ($12.99) / Consensus Forward EPS ($-4.23)
FORWARD PE RATIO
N/A
ArriVent BioPharma, Inc.
Market Cap
$605.01M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | $605.01M | N/A |
| Fulgent Genetics, Inc. (FLGT)vs › | $601.74M | N/A |
| AngioDynamics, Inc. (ANGO)vs › | $610.07M | N/A |
| Ironwood Pharmaceuticals, Inc. (IRWD)vs › | $598.37M | 2.97 |
| OrthoPediatrics Corp. (KIDS)vs › | $582.15M | N/A |
| Climb Bio, Inc. (CLYM)vs › | $637.34M | N/A |
| Aura Biosciences, Inc. (AURA)vs › | $640.57M | N/A |
| Aquestive Therapeutics, Inc. (AQST)vs › | $568.99M | N/A |
| OmniAb, Inc. (OABI)vs › | $643.45M | N/A |
| CytomX Therapeutics, Inc. (CTMX)vs › | $563.87M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $12.99, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-4.23 | $-4.31 – $-4.08 | 7 | n/m |
| 2027-12-31 | $-3.78 | $-4.47 – $-3.31 | 7 | n/m |
| 2028-12-31 | $-1.92 | $-3.77 – $0.33 | 7 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
